RxDoctor Payments Data

Rodney Sturgeon, MD

Family Medicine · Knoxville, TNNPI 1891745436

Payments from drug & device makers

$10,620in general payments, 2019–2025

Across 733 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AbbVie$1K
  • Pfizer$1K
  • Novo Nordisk$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$767
  • Amgen$668
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$10,39998%
  • Education$2212%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,620 in reported general payments places this provider in the 90th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$92,360
Medicare patients
153
Services billed
3,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$142,045
OzempicSemaglutide54$75,720
MounjaroTirzepatide46$44,016
Repatha SureclickEvolocumab44$41,429
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$36,180
JardianceEmpagliflozin34$34,588
MyrbetriqMirabegron19$24,845
VascepaIcosapent Ethyl32$21,396
ShingrixVaricella-Zoster Ge/As01b/Pf94$21,329
TrulicityDulaglutide12$20,236
XareltoRivaroxaban22$17,380
Breo ElliptaFluticasone/Vilanterol15$11,080
Tresiba Flextouch U-100Insulin Degludec16$10,723
SeroquelQuetiapine Fumarate24$7,181
TresibaInsulin Degludec12$3,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,267$142,045123 claims
Novo NordiskOzempic, Tresiba$1,080$79,63166 claims
GSKTrelegy Ellipta, Shingrix, Breo Ellipta$1,415$68,588143 claims
Lilly USA, LLCMounjaro, Trulicity$240$64,25158 claims
Boehringer IngelheimJardiance$498$34,58834 claims
Astellas Pharma US IncMyrbetriq$511$24,84519 claims
Johnson & JohnsonXarelto$50$17,38022 claims
AstraZenecaSeroquel$552$7,18124 claims
AbbVieSynthroid$1,401$1,67239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →